SCHEMBL30734154

SCHEMBL30734154

Fc1ccc(N2CCN(c3ncnc4ccc(Cl)nc34)CC2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.51
ACHE P22303 1/20 0.51
BACE1 P56817 1/20 0.51
SMN1; SMN2 Q16637 3/20 0.50
TP53 P04637 1/20 0.50
THRB P10828 2/20 0.49
HTT P42858 3/20 0.49
CNR1 P21554 1/20 0.48
CNR2 P34972 1/20 0.48
LMNA P02545 2/20 0.48
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
DRD2 P14416 1/20 0.41
DRD4 P21917 1/20 0.41
DRD3 P35462 1/20 0.41
ALDH1A1 P00352 1/20 0.41
MAPK1 P28482 1/20 0.41
GFER P55789 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30734190 0.86 MAPT (0.44) MAPTACHEBACE1SMN1; SMN2THRB
SCHEMBL30734176 0.86 ACHE (0.49) MAPTACHEBACE1SMN1; SMN2TP53
SCHEMBL22715630 0.81 MAP4K4 (0.44) MAPTHTTCNR1ALDH1A1MAPK1
SCHEMBL22715607 0.81 MAP4K4 (0.48) MAPTSMN1; SMN2THRBHTTCNR1
SCHEMBL29439612 0.81 MAP4K4 (0.48) MAPTSMN1; SMN2THRBHTTCNR1
SCHEMBL31114094 0.80 PTK2 (0.54) SMN1; SMN2TP53LMNANPC1RAB9A
SCHEMBL3460263 0.80 PTK2 (0.54) SMN1; SMN2TP53LMNANPC1RAB9A
SCHEMBL22715964 0.80 MAP4K4 (0.50) MAPTSMN1; SMN2HTTCNR1LMNA
SCHEMBL29439801 0.80 MAP4K4 (0.50) MAPTSMN1; SMN2HTTCNR1LMNA
SCHEMBL30734180 0.79 MAPT (0.50) MAPTSMN1; SMN2TP53THRBHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250382301-A1 SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF UNIV ARIZONA (US) 2025-12-18 US disclosed
EP-4543888-A1 SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF Arizona Board of Regents on behalf of The University of Arizona (US) 2025-04-30 EP disclosed
WO-2023250083-A1 SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2023-12-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250382301-A1 SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF CLK2, CLK3, CLK1 MAPT 1251/4885ACHE 3704/4885BACE1 1412/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.